Restenosis revisited.
Patrick A
PA
Calvert
Martin R
MR
Bennett
D000818:Animals; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016893:Carotid Stenosis / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D023903:Coronary Restenosis / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control*; D054855:Drug-Eluting Stents; D004789:Enzyme Activation; D020536:Enzyme Activators / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006965:Hyperplasia; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D009285:Naphthoquinones / Q000008:administration & dosage / Q000627:therapeutic use*; D055502:Secondary Prevention; D017539:Tunica Intima / Q000187:drug effects / Q000201:enzymology / Q000473:pathology
D002317:Cardiovascular Agents; D020536:Enzyme Activators; D009285:Naphthoquinones; C014638:beta-lapachone; D016660:NAD(P)H Dehydrogenase (Quinone); C447479:NQO1 protein, human; C507703:NQO1 protein, rat